ASLAN Pharma today announced that an abstract presented at ESMO Asia 2017 on data from its Phase 2 clinical trial of varlitinib in metastatic HER2-positive breast cancer patients won the Best Poster Award in the breast cancer, metastatic category.
SINGAPORE, January 2, 2018 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that an abstract presented at ESMO Asia 2017 on data from its Phase 2 clinical trial of varlitinib in metastatic HER2-positive breast cancer (HER2+ MBC) patients won the Best Poster Award in the breast cancer, metastatic category.
Varlitinib is a reversible potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs).
The Phase 2 clinical trial compared the efficacy and safety of varlitinib plus capecitabine (VC) versus lapatinib plus capecitabine (LC) in HER2+ MBC patients who failed prior trastuzumab therapy.
Details of the abstract are as follows:
Title: Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.
Abstract Number: 987
A full-text version of the abstract is available online at https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/presentation/list?r=pt~23
Media and IR contacts
| Chris Fang ASLAN Pharmaceuticals Tel: +886 2 2758 3333 E-mail: media@aslanpharma.com | Emma Thompson / Stephanie Tan Spurwing Communications Tel: +65 6340 7287 Email: ASLAN@spurwingcomms.com | Robert H. Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com
|
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 HER3 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumor growth. Varlitinib is currently being studied in biliary tract, gastric, breast and colorectal cancers. Varlitinib has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
